Multiplexed mosaic tumor models reveal natural phenotypic variations in drug response within and between populations
Yu, J. X.; Suh, J. M.; Popova, K. D.; Garcia, K.; Joshi, T.; Culbertson, B.; Spinelli, J. B.; Subramanyam, V.; Lou, K.; Shokat, K. M.; Weissman, J.; Goodarzi, H.
Show abstract
Many agents that show promise in preclinical cancer models lack efficacy in patients due to patient heterogeneity that is not captured in traditional assays. To address this problem, we have developed GENEVA, a platform that measures the molecular and phenotypic consequences of drug perturbations within diverse populations of cancer cells at single-cell resolution, both in vitro and in vivo. Here, we apply GENEVA to study the KRAS G12C inhibitors, recapitulating known properties of these drugs and uncovering a previously unknown role for mitochondrial activation in cell death induced by KRAS inhibition. We demonstrate that this finding can be leveraged for the development of combination therapies with greater efficacy. Finally, we show that the application of GENEVA with in vivo mouse models revealed epithelial to mesenchymal transition (EMT) as a key mechanism for resistance to KRAS G12C inhibition.
Matching journals
The top 4 journals account for 50% of the predicted probability mass.
Similar papers in this journal
Similar papers in this journal
- Rapidly induced drug adaptation mediates escape from BRAF inhibition in single melanoma cells 97%
- Multiplexed single-cell profiling of post-perturbation transcriptional responses to define cancer vulnerabilities and therapeutic mechanism of action 96%
- Resistance to targeted therapies as a multifactorial, gradual adaptation to inhibitor specific selective pressures 96%
Similar papers in this journal
- Conditional lethality profiling reveals anticancer mechanisms of action and drug-nutrient interactions 96%
- Select EZH2 inhibitors enhance the viral mimicry effects of DNMT inhibition through a mechanism involving calcium-calcineurin-NFAT signaling 96%
- Pathogenic mitochondrial DNA mutations inhibit melanoma metastasis 95%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.